Technology area: Biotechnology & Pharmaceuticals
15 pending office actions • 13 art units • 15 examiners • 0 of 15 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
The UAB Research Foundation has 16 pending office actions in Biotechnology & Pharmaceuticals. Those matters involve 16 distinct examiners and 14 art units, showing that prosecution is distributed broadly across the examining corps and technical classifications.
POPA, ILEANA is the busiest examiner, with 1 pending action. No examiner accounts for a concentrated share of the listed workload, so portfolio management should emphasize matter-level tracking, consistent disclosure positions, and coordination across the different art units.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (7%) |
| §103 only | 4 (27%) |
| Double-patenting only | 1 (7%) |
| Multi-statute (no §101) | 9 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POPA, ILEANA | 1 | 21.7% | +15.7% |
| WINAKUR, ERIC FRANK | 1 | 79.3% | +13.8% |
| HAMA, JOANNE | 1 | 25.4% | +40.2% |
| LEE, EDMUND H | 1 | 69.6% | +17.4% |
| TRA, TUYEN Q | 1 | 85.6% | +9.2% |
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
| KWON, YONG SOK | 1 | 24.6% | +42.7% |
| SCHWECHTER, BRANDON ROSS | 1 | 0.0% | +0.0% |
| MATALKAH, FATIMAH KHALAF | 1 | 55.8% | +27.4% |
| SISON, CHRISTINE ANDREA PAN | 1 | 32.7% | +40.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18958046 | Compositions and Methods for Cancer Immunotherapy | POPA, ILEANA | — |
| 18867687 | DEVICES AND METHODS FOR TRANSCUTANEOUS BILIRUBIN MEASUREMENT | WINAKUR, ERIC FRANK | — |
| 18865259 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS | HAMA, JOANNE | — |
| 18836134 | AN ANTI-MYOPIA VISUAL DISPLAY THERAPY USING SIMULATED MYOPIC BLUR | TRA, TUYEN Q | — |
| 18730565 | COMPOSITIONS AND METHODS OF REGENERATING HEART TISSUES WITH AMINOGLYCOSIDES | BERRY, LAYLA D | — |
| 18667950 | GENERATION OF S-NITROSOACETYLCYSTEINE | KWON, YONG SOK | — |
| 18700751 | BMP9 OR AN AGONIST THEREOF AND ITS USES RELATED TO REDUCING METASTASIS OF CANCER | SCHWECHTER, BRANDON ROSS | — |
| 18690101 | METHODS AND FORMULATIONS RELATED TO THE INTRATHECAL DELIVERY OF ONCOLYTIC VIRUSES | MATALKAH, FATIMAH KHALAF | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18337705 | SELECTIVE STIMULATION OF GROUPS OF NEURAL ELEMENTS WITHIN A REGION OF THE BRAIN | SISON, CHRISTINE ANDREA PAN | 60d overdue |
| 18958046 | Compositions and Methods for Cancer Immunotherapy | POPA, ILEANA | — |
| 18867687 | DEVICES AND METHODS FOR TRANSCUTANEOUS BILIRUBIN MEASUREMENT | WINAKUR, ERIC FRANK | — |
| 18865259 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS | HAMA, JOANNE | — |
| 18915925 | INORGANIC FIBER TUBULAR STRUCTURES, AND SYSTEM AND METHOD FOR MANUFACTURING THE INORGANIC FIBER TUBULAR STRUCTURES | LEE, EDMUND H | — |
| 18667950 | GENERATION OF S-NITROSOACETYLCYSTEINE | KWON, YONG SOK | — |
| 18690101 | METHODS AND FORMULATIONS RELATED TO THE INTRATHECAL DELIVERY OF ONCOLYTIC VIRUSES | MATALKAH, FATIMAH KHALAF | — |
| Art Unit | Apps |
|---|---|
| 2872 | 2 |
| 1638 | 2 |
| 1633 | 1 |
| 3791 | 1 |
| 1645 | 1 |
| 1744 | 1 |
| 1693 | 1 |
| 1613 | 1 |
| 1674 | 1 |
| 3796 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18958046 | Compositions and Methods for Cancer Immunotherapy | POPA, ILEANA | 1633 | §103§112Other | Non-Final OA | — | Pending | Nov 25, 2024 |
| 18867687 | DEVICES AND METHODS FOR TRANSCUTANEOUS BILIRUBIN MEASUREMENT | WINAKUR, ERIC FRANK | 3791 | §102§103§112 | Non-Final OA | — | Pending | Nov 20, 2024 |
| 18865259 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS | HAMA, JOANNE | 1645 | §102§103 | Non-Final OA | — | Pending | Nov 12, 2024 |
| 18915925 | INORGANIC FIBER TUBULAR STRUCTURES, AND SYSTEM AND METHOD FOR MANUFACTURING THE INORGANIC FIBER TUBULAR STRUCTURES | LEE, EDMUND H | 1744 | DP | Final Rejection | — | Pending | Oct 15, 2024 |
| 18836134 | AN ANTI-MYOPIA VISUAL DISPLAY THERAPY USING SIMULATED MYOPIC BLUR | TRA, TUYEN Q | 2872 | §102§103 | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18730565 | COMPOSITIONS AND METHODS OF REGENERATING HEART TISSUES WITH AMINOGLYCOSIDES | BERRY, LAYLA D | 1693 | §102§103 | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18667950 | GENERATION OF S-NITROSOACETYLCYSTEINE | KWON, YONG SOK | 1613 | §102§103§112 | Non-Final OA | — | Pending | May 17, 2024 |
| 18700751 | BMP9 OR AN AGONIST THEREOF AND ITS USES RELATED TO REDUCING METASTASIS OF CANCER | SCHWECHTER, BRANDON ROSS | 1674 | §103§112 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18690101 | METHODS AND FORMULATIONS RELATED TO THE INTRATHECAL DELIVERY OF ONCOLYTIC VIRUSES | MATALKAH, FATIMAH KHALAF | 1638 | §103§112 | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18337705 | SELECTIVE STIMULATION OF GROUPS OF NEURAL ELEMENTS WITHIN A REGION OF THE BRAIN | SISON, CHRISTINE ANDREA PAN | 3796 | §103 | Final Rejection | 60d overdue | Pending | Jun 20, 2023 |
| 18315677 | PRE-CLINICAL MODIFIED RNA APPROACHES USED IN LARGE ANIMALS FOR MUSCLE AND VASCULAR REGENERATION | ALLEN, SARAH ELIZABETH | 1637 | §103 | Final Rejection | 16d overdue | Pending | May 11, 2023 |
| 17765926 | MULTI-LAYERED NANOPARTICLE COATED SUBSTRATES FOR DRUG DELIVERY | PARK, HAEJIN S | 1614 | §103 | Final Rejection | 162d overdue | Pending | Apr 01, 2022 |
| 17761806 | MULTI-SPECTRAL AND MULTI-FOCAL CONTROL OF MYOPIA | WILKES, ZACHARY W | 2872 | §101§102§112 | Non-Final OA | — | Pending | Mar 18, 2022 |
| 17479453 | METHOD FOR INCREASING CELL SUSCEPTIBILITY TO COMPLEMENT- MEDIATED LYSIS | COOK, LISA V | 1642 | §103 | Non-Final OA | — | Pending | Sep 20, 2021 |
| 18482869 | Compositions And Methods For Making And Using Atherosclerotic Nanomatrix Vascular Sheets | JACKSON III, WALTER | 1638 | §102§103§112 | Non-Final OA | — | Pending | Oct 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe UAB Research Foundation has 15 pending office actions as of October 2026, spread across 13 art units and 15 examiners.
Ileana Popa has the most, with 1 of The UAB Research Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
